Cushing's Sx Described in Infant Treated With Ophthalmic Steroid

Share this content:
Cushing's Sx Described in Infant Treated With Ophthalmic Steroid
Cushing's Sx Described in Infant Treated With Ophthalmic Steroid

FRIDAY, April 8, 2016 (HealthDay News) -- In a case report published online April 7 in Pediatrics, iatrogenic Cushing's syndrome (ICS) is described in an infant following intranasal usage of dexamethasone ophthalmic solution.

Sarah Orton, M.D., and Marisa Censani, M.D., from Weill Cornell Medicine in New York City, present the case of a 4-month-old male infant who was born at 26 weeks of gestation. He was treated for nasal obstruction with intranasal dexamethasone ophthalmic solution administered for six weeks.

The researchers found that after steroid introduction, the infant's growth velocity had decreased. He was noted to have large ruddy cheeks with moon facies on exam. A morning cortisol level of <0.4 µg/dL was obtained and the patient was diagnosed with ICS. Dexamethasone taper was initiated, with discontinuation by four months post-ophthalmic steroid initiation. His morning cortisol level was 1.6 µg/dL by one month post-steroid use and his Cushingoid facies had resolved by 2.5 months post-steroid use. At 4.5 months following discontinuation of steroids, the infant's hypothalamic-pituitary-adrenal axis had recovered fully.

"Because of the small body surface area and supine position during administration, infants are particularly susceptible to ICS," the authors write. "Close monitoring of these patients' height and weight should occur while on steroid treatment, with every effort made to decrease or discontinue steroid use when possible."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths